Eli Lilly and Company

Eli Lilly posted 47% revenue growth and a 128% EPS jump. Net margin hit 35%. At 44 times earnings, the stock trades near the top of its 52-week range. The Alpha Score sits at 72, driven by momentum and quality readings above 80. Sentiment lags at 50, and value scores a middling 60. The Trump administration floated a plan to raise tariffs on generic drug imports from India — currently 0%, phasing to 200% by 2029. India supplies nearly half of U.S. generic drug volumes. Lilly sells branded drugs, not generics, so the direct exposure looks small. Still, any disruption to the broader pharma supply chain could ripple through the sector. Watch for the next quarterly print. Lilly needs to sustain this growth pace to justify the multiple.

Eli Lilly sits near the top of its 52-week range at $1249.45, with a momentum Alpha Score of 81.4 propelling the overall score to 71.2. Revenue grew 47.4% year over year, while EPS surged 128.8%. The net margin of 35% and quality score of 87 reflect the company's pricing power and operational efficiency. The P/E of 43.93 is high, and the value score of 60 suggests limited upside from multiples alone. A sentiment score of 50 puts it in neutral territory. The next catalyst will be the quarterly earnings report, where revenue growth and margin trajectory will determine whether the stock can hold the high end of its range.

Eli Lilly shares fell 1.2% Tuesday after Q2 revenue of $11.3 billion — up 36% year over year — missed the Mounjaro sales consensus by about $200 million. The GLP-1 franchise still grew sharply, but the bar is high. Full-year guidance was raised, and the company reiterated its 2024 revenue forecast of $45.4 billion to $46.6 billion. The stock trades at 44.3x trailing earnings, with EPS growth of 128.8% and a net margin of 35%. The Alpha Score sits at 69.3, driven by momentum (82.6) and quality (87). Value scores a 59.8; sentiment is weak at 39.3, reflecting the high expectations baked into the multiple. Next watch: the FDA decision on donanemab for early Alzheimer's, expected by year-end. A positive outcome would add a second blockbuster pillar beyond incretins.

Eli Lilly shares held near the top of their 52-week range as news broke that the company is in early talks to acquire psychedelic drugmaker AtaiBeckley. The target's stock surged 66% on the report. Lilly's own fundamental story remains one of the cleanest in healthcare. Revenue grew 47.4% year over year, EPS jumped 128.8%, and net margin hit 35%. The P/E sits at 44.28, a premium that quality and momentum scores justify. The Alpha Score of 68.3 is driven by quality at 87 and momentum at 79.8, while sentiment lags at 38.5. Value scores a middling 59.8. The buyout chatter adds a new dimension. AtaiBeckley's pipeline would bring novel depression and PTSD treatments, but the deal is early stage. Watch for any formal offer or rejection in the coming weeks. Lilly's next quarterly update is due in late April.

Eli Lilly is backing Chai Discovery's $400 million raise at a $3.4 billion valuation, alongside Pfizer. The AI biotech claims 20% hit rates on antibody design, a step toward faster drug development. Lilly's own numbers are strong. Revenue grew 47.4% year over year. EPS jumped 128.8%. Net margin hit 35%. The stock trades at 44.28 times earnings, near the top of its 52-week range of $623.78 to $1249.45. The Alpha Score sits at 68.6, driven by momentum at 80.8 and quality at 87. Value scores lower at 59.8. With earnings growth outpacing revenue, margins are expanding. The next catalyst could be the Chai partnership's progress or the next quarterly report.